Tests KTE-X19 CAR T-cell therapy in adults with leukemia and minimal residual disease
Tests KTE-X19 CAR T-cell therapy in adults with B-cell acute lymphoblastic leukemia.
Key facts
- Who runs it
- H. Lee Moffitt Cancer Center and Research Institute
- Where
- Tampa, United StatesSee the site
- Trial code
- Registry title
- Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 26 Dec 2023
- Expected to end
- 29 Jul 2031
- Type of study
- Interventional
- Treatments tested
- Tecartus
- Record updated
- 25 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with CD19-positive B-cell acute lymphoblastic leukemia who are in remission after induction chemotherapy but still have minimal residual disease (MRD). They would receive KTE-X19 CAR T-cell therapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- CD19-positive B-cell acute lymphoblastic leukemia in complete remission with minimal residual disease (a bone marrow biopsy with fewer than 5% lymphoblasts) after an induction regimen. Any disease outside the bone marrow or in the central nervous system must be resolved.
- Earlier treatment
- Must have had induction chemotherapy and fully recovered from it. A few effects are allowed, such as mild nerve damage from vincristine, diabetes or high blood pressure from steroids or asparaginase, and low blood counts from inotuzumab or chemotherapy. High-dose steroids and other immune-suppressing drugs must be avoided for 7 days before enrollment. No live vaccine in the 4 weeks before enrollment.
- Biomarker or test result
- The leukemia must be CD19 positive, confirmed by pathology.
Main reasons for not taking part
- Burkitt's lymphoma (L3), MLL-rearranged, biphenotypic or mixed phenotype leukemia, or blast phase of chronic myeloid leukemia
- Active infection needing systemic treatment, including HIV, Hepatitis B or Hepatitis C
- Active leukemia in the central nervous system, or a history of a central nervous system disorder such as seizures or dementia
- Recent heart attack or serious heart disease within 12 months, or recent repeated blood clots within 3 months
- Pregnant, breastfeeding, or expecting to conceive or father a child during the trial
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Must be an adult 18 years of age or older
- Pathologically confirmed CD19 positive B-cell acute lymphoblastic leukemia
- Treatment and full recovery from induction chemotherapy, with following exceptions:
- Vincristine associated grade 1 peripheral neuropathy B. Steroid/asparaginase associated diabetes and/or hypertension C. Inotuzumab/chemotherapy associated cytopenias
- Patients must be in a complete remission with Minimal Residual Disease (MRD) following an induction regimen. MRD is defined herein as a bone marrow biopsy with fewer than 5% lymphoblasts. Complete remission implies the resolution of any extramedullary and/or Central Nervous Syndrome (CNS)-2-3/parenchymal disease
- Be willing and able to provide written informed consent/assent for the trial
- Able to adhere to the study visit schedule and other protocol requirements
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate renal, hepatic, pulmonary, cardiac function
- Adequate hematopoietic reserve
- Females of childbearing potential (FCBP) must have a negative serum pregnancy test at screening. A FCBP is considered when a sexually mature female:; has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months
- Subjects of both genders of child-bearing potential must be willing to practice birth control from the time of consent through 6 months after the completion of KTE-X19 infusion
Who cannot take part
- Recurrent thrombosis, or non-central venous catheter associated thrombosis within 3 months prior to enrollment
- History of concomitant genetic syndrome associated with bone marrow failure such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome
- Corticosteroid therapy at a pharmacologic dose (> 5 mg/day of prednisone or equivalent doses of other corticosteroids) and other immunosuppressive drugs must be avoided for 7 days prior to enrollment
- Live vaccine ≤ 4 weeks prior to enrollment
- Any active infection requiring systemic therapy, including HIV, Hepatitis B, and/or Hepatitis C
- History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
- History or presence of any CNS disorder such as a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, any autoimmune disease with CNS involvement, posterior reversible encephalopathy syndrome (PRES), or cerebral edema
- Severe comorbid conditions for which life expectancy would be <6 months
- Patients with active (uncontrolled, metastatic) second malignancies are excluded
- Primary immunodeficiency or history of autoimmune disease (Crohns, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator (including but not limited to unstable angina, pre-existing liver disease, recurrent pancreatitis, uncontrolled diabetes, hypertriglyceridemia, pulmonary hypertension, or severe Congestive Heart Failure (CHF)
- Diagnosis of L3 type Burkitt's lymphoma, Mixed-Lineage Leukemia (MLL) rearranged leukemia, biphenotypic leukemia, mixed phenotype acute leukemia, blast phase of chronic myeloid leukemia, or stem-cell leukemia
- Active CNS/leptomeningeal leukemia
- Presence of any indwelling line or drain (percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter). Ommaya reservoirs and dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter are permitted
- Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of trial treatment
Where in United States
- Moffitt Cancer CenterTampa, United StatesContact: Bijal D. Shah, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
The group in the trial
- Autologous CAR T-cell immunotherapyTreatment being tested
Tecartus will be delivered at a target dose of 1x106 cells / kg. For those \>100 kg, a flat dose of 1 x108 cells will be used. Tecartus will be administered on day 0, following 1 day of rest from conditioning chemotherapy.
Treatment: Tecartus
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 2 Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Plain-language title
- Tests KTE-X19 CAR T-cell therapy in adults with leukemia and minimal residual diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 September 2026